NEW YORK, March 14 - Boston Biomedica on Thursday said it has been awarded a $701,000 Phase II Small Business Innovation Research grant to help develop and commercialize its Pressure Cycling Technology.
The technology is used to "release DNA, RNA, and proteins from cells and tissues, with particular emphasis on hard-to-lyse biomaterials," Boston Biomedica said.
The money will also go toward studies of new life-sciences applications for the PCT sample preparation system, which the company will launch at Pittcon 2002 in New Orleans next week.
"This grant will permit BBI to further expand its usage to important applications in plant and animal genomics and proteomics, in addition to uses already under study, such as processing human tissues for cancer diagnosis or genetic abnormalities," Richard T. Schumacher, founder, chairman and CEO of Boston Biomedica, said in a statement.
According to Boston Biomedica, a "major advantage of the PCT sample preparation system over other methods is that PCT conditions can be controlled to preserve the activity of released material, including intact RNA and biologically active proteins, making it especially relevant for the study of gene expression."
This is the second Phase II SBIR grant the company has been awarded for its PCT technology. Last fall Boston Biomedica, of West Bridgewater, Mass., won $760,000 over two years to apply PCT "to the inactivation of viruses in blood plasma while preserving the plasma's therapeutic properties."